Novo Nordisk : NVO

All Novo Nordisk Articles

172 Articles

Joel South | Apr 25, 2025 at 9:44 AM EDT

S&P 500 (VOO) Live: Alphabet Up, Market Down But Improving Already

And we’re off! The stock market opened for trading a bit lower today than it left off last night. But…

Joel South | Apr 21, 2025 at 9:45 AM EDT

Live Market Update: S&P 500 Opens Lower on Political Rumblings in Washington

Stock market indices opened lower Monday after a three-day weekend, over the course of which President Trump criticized, and even…

Rich Duprey | Apr 17, 2025 at 10:08 AM EDT

These 2 Dividend Giants Are at 52-Week Lows. Time to Buy?

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through…

Omor Ibne Ehsan | Apr 3, 2025 at 2:58 PM EDT

3 Rock-Solid Dividend Stocks That Will Grow Passive Income This Year

Dividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These…

Rich Duprey | Feb 25, 2025 at 12:41 PM EST

HIMS Stock Craters – Is It a Buying Opportunity?

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said…

Rich Duprey | Feb 24, 2025 at 12:36 PM EST

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO | NVO…

Ian Cooper | Feb 21, 2025 at 11:47 AM EST

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is…

Trey Thoelcke | Feb 14, 2025 at 8:45 AM EST

AbbVie Just Paid Investors: Here’s How Much They Received

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50…

Joey Frenette | Jan 23, 2025 at 12:01 PM EST

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After…

Omor Ibne Ehsan | Jan 22, 2025 at 11:15 AM EST

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Eli Lilly (NYSE: LLY | LLY Price Prediction) doesn’t really need much of an introduction. It has become a household…

Rich Duprey | Jan 21, 2025 at 3:15 PM EST

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has been described as the best pure-play stock in artificial intelligence. The market…

Rich Duprey | Jan 15, 2025 at 9:06 AM EST

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly…

Omor Ibne Ehsan | Dec 17, 2024 at 8:58 AM EST

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

The Dow Jones is one of Wall Street’s most iconic benchmarks and it tracks 30 of America’s largest companies. It…

Will Ashworth | Nov 7, 2024 at 11:12 AM EST

These 3 Stocks Are Winning Thanks to Baby Boomers

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or…

Rich Duprey | Oct 3, 2024 at 7:53 PM EDT

Is John Paulson’s Best Investment Ever a Buy or Sell

The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the…

1 … 4 5 6 7 8 … 12

Novo Nordisk : NVO

All Novo Nordisk Articles

S&P 500 (VOO) Live: Alphabet Up, Market Down But Improving Already

Live Market Update: S&P 500 Opens Lower on Political Rumblings in Washington

These 2 Dividend Giants Are at 52-Week Lows. Time to Buy?

3 Rock-Solid Dividend Stocks That Will Grow Passive Income This Year

HIMS Stock Craters – Is It a Buying Opportunity?

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

AbbVie Just Paid Investors: Here’s How Much They Received

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

These 3 Stocks Are Winning Thanks to Baby Boomers

Is John Paulson’s Best Investment Ever a Buy or Sell

The Average Social Security Check Is $2,082. Your Bills Didn’t Get the Memo. These 4 ETFs Step In

What It Takes to Retire to Delaware’s Beaches at 62 on $800,000 and Skip Florida Entirely

You’re 62 With $400K Earning 0.6% at the Bank. These 3 ETFs Put It to Work Before You Retire

What It Takes to Retire to Delaware's Beaches at 62 on $800,000 and Skip Florida Entirely

Retiring on a Cruise Ship Costs Less Than You Think. Until It Doesn't.

The Average Social Security Check Is $2,082. Your Bills Didn’t Get the Memo. These 4 ETFs Step In

What It Takes to Retire to Delaware’s Beaches at 62 on $800,000 and Skip Florida Entirely

Novo Nordisk : NVO

All Novo Nordisk Articles

S&P 500 (VOO) Live: Alphabet Up, Market Down But Improving Already

Live Market Update: S&P 500 Opens Lower on Political Rumblings in Washington

These 2 Dividend Giants Are at 52-Week Lows. Time to Buy?

3 Rock-Solid Dividend Stocks That Will Grow Passive Income This Year

HIMS Stock Craters – Is It a Buying Opportunity?

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

AbbVie Just Paid Investors: Here’s How Much They Received

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider

Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?

These 3 Stocks Are Winning Thanks to Baby Boomers

Is John Paulson’s Best Investment Ever a Buy or Sell

The Average Social Security Check Is $2,082. Your Bills Didn’t Get the Memo. These 4 ETFs Step In

What It Takes to Retire to Delaware’s Beaches at 62 on $800,000 and Skip Florida Entirely

You’re 62 With $400K Earning 0.6% at the Bank. These 3 ETFs Put It to Work Before You Retire

Featured Reads

What It Takes to Retire to Delaware's Beaches at 62 on $800,000 and Skip Florida Entirely

Retiring on a Cruise Ship Costs Less Than You Think. Until It Doesn't.